SFS
PTGX icon

Sowell Financial Services’s Protagonist Therapeutics PTGX Stock Holding History

Sowell Financial Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$28K – 2166
2021
Q1 		$28K Hold
1,000
– – ﹤0.01% 1905
2020
Q4 		$20K Hold
1,000
– – ﹤0.01% 1751
2020
Q3 		$20K Buy
1,000
+465
+87% +$8.73K ﹤0.01% 1566
2020
Q2 		$9K Buy
+535
New +$6.71K ﹤0.01% 1734

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Sowell Financial Services's PTGX Position: Q2 2021 in Review

Sowell Financial Services sold out of Protagonist Therapeutics (PTGX) in Q2 2021, closing a stake of 1,000 shares — an estimated $28K sold.

Sowell Financial Services first reported a position in PTGX in Q2 2020 and held it in 4 quarters. The position peaked at $28K in Q1 2021. 138 funds tracked by Wall St. Rank hold PTGX as of Q2 2021.

  • Sowell Financial Services reported no remaining Protagonist Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 1,000 Protagonist Therapeutics shares in Q2 2021, an estimated $28K.
  • Sowell Financial Services first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 4 quarters.
  • Sowell Financial Services's Protagonist Therapeutics position peaked at $28K in Q1 2021.
  • 138 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.